Targeted mutagenesis of Lis1 disrupts cortical development and LIS1 homodimerization

Lissencephaly is a severe brain malformation in humans. To study the function of the gene mutated in lissencephaly (LIS1), we deleted the first coding exon from the mouse Lis1 gene. The deletion resulted in a shorter protein (sLIS1) that initiates from the second methionine, a unique situation because most LIS1 mutations result in a null allele. This mutation mimics a mutation described in one lissencephaly patient with a milder phenotype. Homozygotes are early lethal, although heterozygotes are viable and fertile. Most strikingly, the morphology of cortical neurons and radial glia is aberrant in the developing cortex, and the neurons migrate more slowly. This is the first demonstration, to our knowledge, of a cellular abnormality in the migrating neurons after Lis1 mutation. Moreover, cortical plate splitting and thalomocortical innervation are also abnormal. Biochemically, the mutant protein is not capable of dimerization, and enzymatic activity is elevated in the embryos, thus a demonstration of the in vivo role of LIS1 as a subunit of PAF-AH. This mutation allows us to determine a hierarchy of functions that are sensitive to LIS1 dosage, thus promoting our understanding of the role of LIS1 in the developing cortex.This work was supported in part by the Fritz Thyssen Stiftung Foundation, Binational Science Foundation Grant No. 97–00014 (to O.R.), a grant from the Seneca Foundation of Murcia community, 708/CV/99 (to S.M.), a grant from the European Community, EC PL-960146 (to O.R., S.M., and W.W.), Human Frontier Science Program Organization Grant No. RG283199 9 (to O.R. and S.K.M.), and Volkswagen Stiftung (to O.R. and W.W.). O.R. is an Incumbent of the Aser Rothstein Career Development Chair in Genetic Diseases (Weizmann Institute).Peer reviewe